Market
89bio reports positive Phase 2b MASH results by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from 89bio Inc. or press releases
Story
Akero's $AKRO Stock Surges 100% on Positive MASH Cirrhosis Results, Boosts $ETNB
Jan 27, 2025, 11:51 AM
Akero Therapeutics Inc. ($AKRO) has reported preliminary topline results from its Phase 2b SYMMETRY study, showing a statistically significant reversal of compensated cirrhosis (F4) due to metabolic-associated steatohepatitis (MASH) at Week 96. The study demonstrated a 24-point difference in liver fibrosis improvement, with 39% of patients on efruxifermin showing improvement compared to 15% on placebo. Both completer and intent-to-treat (ITT) analyses indicated a statistically significant outcome, with the ITT analysis showing a 17% improvement over the expected 10%. The positive results have led to a significant pre-market increase in Akero's stock, trading 100% higher. The success of Akero's study is also seen as beneficial for competitors like 89bio Inc. ($ETNB), with its stock also experiencing gains, reaching up to $12.
View original story
Similar markets
Moderate improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
No improvement • 25%
FDA approval submission • 25%
Other • 25%
Partnership with a major pharmaceutical company • 25%
Phase 3 trial initiation • 25%
Other • 25%
FDA (United States) • 25%
EMA (European Union) • 25%
PMDA (Japan) • 25%
Trial 2 • 25%
All trials conclude simultaneously • 25%
Trial 3 • 25%
Trial 1 • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Worse outcomes • 25%
No improvement • 25%
Moderate improvement • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
